Neurotechnology

I do not think CMS can be restructured any time soon. However, if the community of physicians, scientists, regulators, and people living with these conditions can sculpt good legislation ideas, that they could hand it off to patient advocacy groups who would then press members of Congress (both Senate and House) to get a specific iBCI-coverage bill that ensured  coverage based on function and biomarker not disease etiology payment of entire care pathway, not just device-one-a

How hybrid biological-artificial intelligence systems could transform medical AI by learning the way humans do Part I: The Vision (TL;DR)...

DRAFT WHITE PAPER: Prepared for the Implantable Brain-Computer Interface Collaborative Community (iBCI-CC) Executive Summary As invasive...

As invasive brain-computer interface (iBCI) companies race toward FDA approval, they face a critical strategic decision that will...

A comprehensive blueprint for creating sustainable, evidence-based pain rehabilitation programs that serve patients, preserve surgical...

Part I: The Vision - A New Paradigm for Neurological Recovery The Problem We Must Solve Millions of people live with neurological...

What if the next leap in computing doesn’t come from faster GPUs or more efficient transformer models, but from a living system that...

A roadmap for navigating the bandwidth bottleneck between biological and artificial intelligence Neural tissue and silicon firmware can communicate directly with each other both in vitro and in vivo. © 2025, Mijail D. Serruya The Fundamental Problem Current brain-computer interfaces are impressive—and we can ask: are they 'just' a more direct equivalent to screen-and-keyboard, or are something fundamentally different? Are we trying to squeeze the entire ba

"I have a queer sensation as if I am not here... As though I were half here and half not here." When Wilder Penfield's electrode touched...

TL;DR : With nearly $1 billion invested in implantable brain-computer interfaces, investors expect a 10x return on a $10 billion market. Yet the path to this scale requires fundamental shifts beyond technical innovation—from regulatory frameworks to reimbursement models, from device-centric thinking to platform ecosystems, and from passive medical devices to living pharmaceutical systems that partner with human agency. The Cochlear Implant Benchmark: A 70-Year Reality Check W

I do not think it is possible to strip the discovery of new knowledge from the cultural and political context of which emerges, and I do...